Kaneko Kensuke, Kawai Kazushige, Kazama Shinsuke, Murono Koji, Sasaki Kazuhito, Yasuda Koji, Ohtani Kensuke, Nishikawa Takeshi, Tanaka Toshiaki, Kiyomatsu Tomomichi, Hata Keisuke, Nozawa Hiroaki, Ishihara Soichiro, Morikawa Teppei, Fukayama Masashi, Watanabe Toshiaki
Department of Surgical Oncology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Department of Pathology, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Surg Today. 2017 Jun;47(6):697-704. doi: 10.1007/s00595-016-1419-0. Epub 2016 Sep 22.
The clinical implications of mucinous components in rectal tumors, especially with regard to the efficacy of neoadjuvant chemoradiotherapy, remain unclear.
One hundred and thirty rectal cancer patients who received curative resection after neoadjuvant chemoradiotherapy were retrospectively reviewed. Patients were classified into 3 groups according to the proportion of extracellular mucin: low (<5 %), moderate (5-25 %), and high (>25 %).
There were 82 (63.1 %), 26 (20.0 %), and 22 (16.9 %) patients in the low, moderate, and high mucin groups, respectively. Patients with a high mucinous tumor component were significantly more likely to have an advanced tumor stage (p = 0.010) and a shorter disease-free (p = 0.002) and distant recurrence-free survivals (p < 0.001), whereas the mucinous tumor component showed no correlation with local recurrence (p = 0.101). A high mucinous component was also an independent predictive factor for a shorter disease-free survival (p = 0.041, hazard ratio = 2.56) and distant recurrence-free survival (p = 0.001, hazard ratio = 5.74) according to a multivariate analysis.
Because the mucinous components showed little correlation with local recurrence, mucinous cancer should not be a determining factor for chemoradiotherapy. However, the frequent occurrence of metachronous distant metastasis among patients with a high mucin component makes this a possible indicator for more robust postoperative adjuvant treatment and close surveillance of recurrence.
直肠肿瘤中黏液成分的临床意义,尤其是在新辅助放化疗疗效方面,仍不明确。
回顾性分析130例接受新辅助放化疗后行根治性切除的直肠癌患者。根据细胞外黏液比例将患者分为3组:低黏液组(<5%)、中黏液组(5%-25%)和高黏液组(>25%)。
低黏液组、中黏液组和高黏液组分别有82例(63.1%)、26例(20.0%)和22例(16.9%)患者。高黏液肿瘤成分的患者更有可能处于肿瘤晚期(p = 0.010),无病生存期(p = 0.002)和远处无复发生存期更短(p < 0.001),而黏液肿瘤成分与局部复发无相关性(p = 0.101)。多因素分析显示,高黏液成分也是无病生存期较短(p = 0.041,风险比 = 2.56)和远处无复发生存期较短(p = 0.001,风险比 = 5.74)的独立预测因素。
由于黏液成分与局部复发相关性较小,黏液癌不应作为放化疗的决定因素。然而,高黏液成分患者中异时性远处转移的频繁发生使其可能成为更强有力的术后辅助治疗和密切复发监测的指标。